top of page
The Professional Network for Healthcare Experts
Kelun’s Merck-Partnered ADC Delivers Phase III Win in First-Line PD-L1-Negative Lung Cancer
Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.
nuaxia
Jul 173 min read
Biogen Advances Tau-Targeting Alzheimer’s Drug Diranersen Despite Phase II Dose Uncertainty
Detailed CELIA trial results show Biogen and Ionis’ diranersen slowed cognitive decline in early Alzheimer’s disease, but questions remain over why the lowest dose delivered the strongest clinical benefit.
nuaxia
Jul 154 min read
AstraZeneca and Ionis Miss Primary Endpoint in Phase III ATTR-CM Trial for Eplontersen
The setback clouds expansion plans for the RNA-targeted therapy after a pivotal cardiovascular outcomes study failed to demonstrate a significant benefit in patients with transthyretin amyloid cardiomyopathy.
nuaxia
Jul 103 min read
Thermo Fisher and Arcturus Partner to Advance Phase III ARCT-032 Cystic Fibrosis Programme
The collaboration will integrate manufacturing, clinical research, and commercial readiness services to support late-stage development of a next-generation mRNA therapy.
nuaxia
Jul 52 min read
Celea Therapeutics Secures $180m to Advance Phase III IPF Programme
Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.
nuaxia
Jul 52 min read
Parabilis Medicines Files IPO to Fund Phase III Expansion of Helicon-Based Oncology Pipeline
The move comes just days after a multi-billion dollar partnership with Regeneron, signalling strong investor appetite for next-generation intracellular targeting platforms.
nuaxia
May 273 min read
bottom of page